Pliant Therapeutics entered a new $50.0 million ATM sales agreement with Leerink Partners and terminated its prior 2021 sales agreement with Cantor Fitzgerald without penalties.
Key takeaways
Company entered a 2026 Sales Agreement with Leerink Partners LLC for an at-the-market offering program.
The new ATM program allows for the sale of common stock with an aggregate offering price of up to $50.0 million.
The Company terminated the 2021 Sales Agreement with Cantor Fitzgerald & Co. effective March 27, 2026.
No termination penalties were incurred, and no shares were sold under the terminated 2021 agreement.